AVROBIO AVRO Stock
AVROBIO Price Chart
AVROBIO AVRO Financial and Trading Overview
| AVROBIO stock price | 1.4 USD |
| Previous Close | 1.1 USD |
| Open | 1.08 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 800 |
| Day's Range | 1.08 - 1.13 USD |
| 52 Week Range | 0.56 - 1.93 USD |
| Volume | 562.96K USD |
| Avg. Volume | 2.27M USD |
| Market Cap | 48.96M USD |
| Beta (5Y Monthly) | 1.577216 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.58 USD |
AVRO Valuation Measures
| Enterprise Value | -5475414 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.70253164 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.9234609 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.055 |
Trading Information
AVROBIO Stock Price History
| Beta (5Y Monthly) | 1.577216 |
| 52-Week Change | 16.84% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.93 USD |
| 52 Week Low | 0.56 USD |
| 50-Day Moving Average | 0.94 USD |
| 200-Day Moving Average | 0.93 USD |
AVRO Share Statistics
| Avg. Volume (3 month) | 2.27M USD |
| Avg. Daily Volume (10-Days) | 1.4M USD |
| Shares Outstanding | 44.11M |
| Float | 28.03M |
| Short Ratio | 0.26 |
| % Held by Insiders | 2.65% |
| % Held by Institutions | 52.86% |
| Shares Short | 1.42M |
| Short % of Float | 3.71% |
| Short % of Shares Outstanding | 3.23% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -48.98% |
| Return on Equity (ttm) | -102.99% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -99867000 USD |
| Net Income Avi to Common (ttm) | -101014000 USD |
| Diluted EPS (ttm) | -2.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 72.33M USD |
| Total Cash Per Share (mrq) | 1.64 USD |
| Total Debt (mrq) | 18.34M USD |
| Total Debt/Equity (mrq) | 34.6 USD |
| Current Ratio (mrq) | 5.403 |
| Book Value Per Share (mrq) | 1.202 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -89478000 USD |
| Levered Free Cash Flow (ttm) | -52597500 USD |
Profile of AVROBIO
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 100 Technology Square |
| ZIP | 02139 |
| Phone | 617 914 8420 |
| Website | https://www.avrobio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 78 |
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For AVROBIO Stock
What is a current AVRO stock price?
AVROBIO AVRO stock price today per share is 1.4 USD.
How to purchase AVROBIO stock?
You can buy AVRO shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AVROBIO?
The stock symbol or ticker of AVROBIO is AVRO.
Which industry does the AVROBIO company belong to?
The AVROBIO industry is Biotechnology.
How many shares does AVROBIO have in circulation?
The max supply of AVROBIO shares is 3.74M.
What is AVROBIO Price to Earnings Ratio (PE Ratio)?
AVROBIO PE Ratio is 0.00000000 now.
What was AVROBIO earnings per share over the trailing 12 months (TTM)?
AVROBIO EPS is 0 USD over the trailing 12 months.
Which sector does the AVROBIO company belong to?
The AVROBIO sector is Healthcare.
AVROBIO AVRO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}